{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:25:15Z","timestamp":1791033915242,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.bcmd.2010.02.005","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T05:55:40Z","timestamp":1267077340000},"page":"229-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype"],"prefix":"10.1016","volume":"44","author":[{"given":"P.P.","family":"Landburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Teerlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Biemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.M.","family":"Brandjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.J.","family":"Muskiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Duits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Schnog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bcmd.2010.02.005_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ajh.21475","article-title":"Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions","volume":"84","author":"Kato","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.bcmd.2010.02.005_bib2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.freeradbiomed.2008.01.008","article-title":"Sickle cell disease vasculopathy: a state of nitric oxide resistance","volume":"44","author":"Wood","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bcmd.2010.02.005_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.294.1.81","article-title":"Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease","volume":"294","author":"Morris","year":"2005","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.bcmd.2010.02.005_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide in sickle cell disease","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bcmd.2010.02.005_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00277-004-0856-9","article-title":"Evidence for a metabolic shift of arginine metabolism in sickle cell disease","volume":"83","author":"Schnog","year":"2004","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2010.02.005_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2006.07.001","article-title":"Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes","volume":"21","author":"Kato","year":"2007","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcmd.2010.02.005_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00277-004-0983-3","article-title":"Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease","volume":"84","author":"Schnog","year":"2005","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.bcmd.2010.02.005_bib8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3324\/haematol.12928","article-title":"Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension","volume":"93","author":"Landburg","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bcmd.2010.02.005_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.2009.07658.x","article-title":"Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death","volume":"145","author":"Kato","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.bcmd.2010.02.005_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3324\/haematol.12152","article-title":"Mac Gillavry MR, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice","volume":"93","author":"van Beers","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2010.02.005_bib11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood.V94.5.1555","article-title":"Sickle cell acute chest syndrome: pathogenesis and rationale for treatment","volume":"94","author":"Stuart","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcmd.2010.02.005_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/abio.2001.5575","article-title":"Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography","volume":"303","author":"Teerlink","year":"2002","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.bcmd.2010.02.005_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ab.2006.03.010","article-title":"Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column","volume":"353","author":"de Jong","year":"2006","journal-title":"Anal. Biochem."},{"issue":"851(1\u20132)","key":"10.1016\/j.bcmd.2010.02.005_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jchromb.2006.07.024","article-title":"HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids","volume":"15","author":"Teerlink","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"7","key":"10.1016\/j.bcmd.2010.02.005_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.21184","article-title":"Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis","volume":"83","author":"Landburg","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.bcmd.2010.02.005_bib16","doi-asserted-by":"crossref","first-page":"e2095","DOI":"10.1371\/journal.pone.0002095","article-title":"Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain","volume":"3","author":"Taylor","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcmd.2010.02.005_bib17","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2005-06-2373","article-title":"Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease","volume":"107","author":"Kato","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcmd.2010.02.005_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.hrtlng.2007.05.010","article-title":"Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases","volume":"37","author":"Zakynthinos","year":"2008","journal-title":"Heart Lung"},{"issue":"5","key":"10.1016\/j.bcmd.2010.02.005_bib19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","article-title":"Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension","volume":"129","author":"Fijalkowska","year":"2006","journal-title":"Chest"},{"issue":"296(3)","key":"10.1016\/j.bcmd.2010.02.005_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jama.296.3.310","article-title":"N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease","volume":"19","author":"Machado","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bcmd.2010.02.005_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.11136","article-title":"Pulmonary hypertension in patients with sickle cell\/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations","volume":"92","author":"Voskaridou","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcmd.2010.02.005_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1378\/chest.108.5.1214","article-title":"The heart in sickle cell anemia. The Cooperative Study of Sickle Cell disease (CSSCD)","volume":"108","author":"Covitz","year":"1995","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.bcmd.2010.02.005_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/ajh.21272","article-title":"Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension","volume":"83","author":"van Beers","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bcmd.2010.02.005_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.21016","article-title":"Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency","volume":"83","author":"Gordeuk","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"350(9)","key":"10.1016\/j.bcmd.2010.02.005_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"26","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979610000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979610000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:26:25Z","timestamp":1761049585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979610000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1079979610000392"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2010.02.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2010.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}